Most of the argument about BPC-157 happens in gyms, forums and clinic marketing copy. In October 2025 it happened in a peer-reviewed journal instead — and one side put a number on something people have suspected for years. In a formal published reply, a Polish research team wrote that more than 80% of all records indexed under "BPC 157" trace back to a single research group. If you've been searching what is BPC-157, whether BPC-157 research is solid, or is BPC-157 legal in Australia, that single figure explains more than any mechanism diagram will.

The exchange: review, comment, reply

The sequence is worth following because it's rare to see this play out in print.

In February 2025, Józwiak, Bauer, Kamysz and Kleczkowska published Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review in Pharmaceuticals. It was broadly sceptical: it catalogued the claimed effects, the patent landscape, and then raised concerns — that a compound promoting angiogenesis and upregulating nitric oxide signalling carries theoretical risks (tumour vascularisation, free-radical damage) that nobody has excluded in humans.

In October 2025, Sikiric and colleagues — the Zagreb-based group that has driven BPC-157 research since the 1990s — published a formal Comment rejecting several of those points. Their argument, in short: BPC-157 acts as a cytoprotective agent that modulates angiogenesis and the NO system rather than simply switching them on, that the toxicity concerns misread the underlying data (they note the toxicity assessment involved dosing at 2 g/kg), and that their own work points to anti-tumour rather than pro-tumour behaviour.

The original authors then replied in the same issue. Their central counter wasn't about nitric oxide at all. It was about who has done the work.

The 80% figure

The reply states that over 80% of all records under "BPC 157" are linked to P. Sikiric's group, and that the experiments routinely employ only a single dose of the compound.

Neither of those is an accusation of misconduct, and it shouldn't be read as one. Plenty of legitimate compounds started life in one laboratory. But they are two specific, checkable structural weaknesses:

  • Concentration of authorship. When one group generates most of the literature, "dozens of positive studies" stops being dozens of independent confirmations. Shared methods, shared reagents, shared assumptions and shared analytical choices travel with the group. Independent replication is the mechanism that catches those — and here it's thin.
  • Single-dose designs. Without a dose–response curve, you can't distinguish a real pharmacological effect from a fortunate dose selection, and you can't scale anything to humans. This is a large part of why the "standard" doses circulating online have no experimental basis: the underlying studies were never designed to produce one.

Independent BPC-157 work does exist — pharmacokinetic studies in rats and dogs have come from other groups, for instance. It's just a minority of the file.

What the rest of the evidence base looks like

The 2025 HSS Journal systematic review by Vasireddi and colleagues searched PubMed, Cochrane and Embase through June 2024 for BPC-157 in orthopaedic sports medicine. It found 36 studies: 35 preclinical, one clinical. The authors concluded the evidence does not support clinical use and cautioned clinicians and athletes against it.

A separate 2025 narrative review in Current Reviews in Musculoskeletal Medicine ("Regeneration or Risk?", University of Utah group) reached a similar position — regenerative signals across many animal models, and an absence of the human trials that would turn those signals into evidence.

So the picture is consistent across independent reviewers: the animal literature is large and largely favourable; the human literature is close to empty; and the animal literature itself is concentrated in one centre.

The registered trial that never reported

There is one frequently cited registry entry: NCT02637284, a Phase 1 safety and pharmacokinetics study of an oral BPC-157 tablet (PCO-02 / "Bepecin"), sponsored by PharmaCotherapia d.o.o. — a real company, which matters, because peptide registries also carry demonstration records with fictional sponsors. The trial was registered in 2015, its status has read "unknown" since, results submission was cancelled in 2016, and nothing was ever published.

A registered trial with no reported outcome is not evidence of anything. It's a gap. Ten years on, it's still the closest thing BPC-157 has to a completed human safety study of record.

Is BPC-157 legal in Australia?

This is where Australian readers should be precise, because the regulatory position is much clearer than the science.

Following the ACMS #43 process, the TGA entered BPC-157 into Schedule 4 (Prescription Only Medicine) and Appendix D, clause 5 of the Poisons Standard, effective 1 June 2024. Appendix D clause 5 is reserved for substances where possession without authority is illegal — the TGA's stated reasoning was significant potential for illicit diversion or abuse warranting particular control of possession, without meeting the bar for Schedule 8.

The practical consequences:

  • BPC-157 is not an approved medicine anywhere in the world, including Australia. There is no registered product for a prescriber to prescribe.
  • Possession in Australia without the relevant authority is unlawful — not merely unapproved.
  • "Research use only" labelling on a vial does not change any of this. The UK's MHRA opened an inquiry in April 2026 into clinics advertising peptides including BPC-157 with stated benefits and pricing while labelling them research-only; the regulator's position was that medicinal claims make a product a medicine regardless of the disclaimer. Australian law works on the same logic.
  • WADA has prohibited BPC-157 at all times, in and out of competition, since 2022. Any Australian athlete in a tested pathway should treat that as settled.
  • In the United States, the FDA compounding position shifted through 2026 — BPC-157 left Category 2 in April after a nomination was withdrawn, and the July Pharmacy Compounding Advisory Committee vote is advisory only. It remains not lawfully compoundable, and none of it has any bearing on Australian scheduling.

You can read the full profile on our BPC-157 page, or compare it against other compounds in the peptides section.

What would actually change the picture

Not another animal study. The specific things the October 2025 reply asked for are the specific things missing:

  1. Independent groups reproducing the core healing findings with pre-registered protocols.
  2. Multi-dose designs that generate a dose–response relationship.
  3. Long-term safety data, particularly addressing the angiogenesis question that both sides agree is theoretically live even as they disagree about its direction.
  4. A published human trial — Phase 1, reported, with results.

Until at least the first two arrive, the honest summary is that BPC-157 has a large, internally consistent, mostly single-source animal literature and effectively no human evidence.

Join the free updates list and we'll cover it when independent replication or a reported human trial actually lands.

FAQ

What is BPC-157?

BPC-157 is a synthetic 15–amino-acid peptide derived from a sequence identified in human gastric juice, studied mainly in animal models of tendon, ligament, muscle and gut injury. It is not an approved medicine in any country.

Is BPC-157 legal in Australia?

No. Since 1 June 2024 BPC-157 has been in Schedule 4 and Appendix D, clause 5 of the Poisons Standard, meaning possession without the relevant authority is illegal. There is also no approved product available to prescribe.

Are there any human clinical trials of BPC-157?

Effectively none that have reported. The 2025 HSS Journal systematic review found 35 of 36 studies were preclinical, and the main registered human trial (NCT02637284) has had an unknown status since 2015 with no results ever published.

Does one research group really do most BPC-157 research?

A peer-reviewed reply published in Pharmaceuticals in October 2025 states that over 80% of records indexed under "BPC 157" are linked to P. Sikiric's group. That group disputes the reviewers' safety interpretations but the concentration of authorship is a genuine replication gap.

Sources

This article is independent information, not medical advice. BPC-157 is not an approved medicine in Australia or any other country, is Schedule 4 + Appendix D under the Poisons Standard, and is prohibited by WADA. retatrutide.net.au is editorially independent and does not sell or source peptides.